Baxter International, Inc.

719 articles with Baxter International, Inc.

• 

  A Look at the Top 10 Medical Device Companies in 2018

  6/12/2018

  The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.

• Baxter Unveiled Updates to SHARESOURCE Remote Patient Management Platform for Home Dialysis Patients at ERA-EDTA 2018

  5/30/2018

  Baxter International Inc. announced the availability of two program updates for its SHARESOURCE remote patient management platform to support greater accessibility and efficiencies in remotely viewing patient data.

• Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress That Further Demonstrate Value of HDx Therapy Enabled by THERANOVA

  5/30/2018

  Baxter International Inc. announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer.

• Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference

  5/21/2018

  Company Increases Financial Guidance for 2020 and Provides Outlook for 2023

• Baxter Announces U.S. FDA Clearance of New Spectrum IQ Infusion System

  5/14/2018

  Designed with Exclusive New Features for Bi-Directional Electronic Medical Records Integration Including Auto-Programming and Auto-Documentation

• Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease

  5/2/2018

  Baxter International Inc. announced a partnership to advance chronic kidney disease (CKD) awareness and help improve access to therapy, particularly in low- and middle-income countries (LMIC) – commonly referenced as emerging markets – where the disease prevalence is growing the fastest.

• Baxter Reports First-Quarter 2018 Results and Increases Financial Outlook for Full-Year 2018

  4/26/2018

  First-Quarter Revenue of $2.7 Billion Increased 8 Percent on a Reported Basis and 3 Percent on an Operational Basis

• Baxter to Host First Quarter 2018 Financial Results Conference Call for Investors

  4/4/2018

  Baxter International, Inc. will host a conference call to discuss its first quarter 2018 financial results on Thursday, April 26, 2018, at 7:30 a.m. Central Daylight Time.

• Baxter International Inc. to Host Webcast of Annual Meeting of Stockholders

  4/2/2018

  Baxter International, Inc. will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time.

• 

  The Big Tease: Takeda Considers Buying Shire

  3/28/2018

  Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.

• Baxter Completes Acquisition of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio

  3/19/2018

  RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin and PREVELEAK Surgical Sealant is used in vascular reconstruction.

• Baxter Declares Quarterly Dividend and Announces Expanded Share Repurchase Authorization

  2/20/2018

  Baxter International Inc. (NYSE:BAX) today announced a quarterly cash dividend and an expanded authorization for its share repurchase program.

• Baxter to Present at the Raymond James & Associates 39th Annual Institutional Investors Conference

  2/7/2018

  Baxter will present at the Raymond James & Associates 39th Annual Institutional Investors Conference on Tuesday, March 6, 2018, in Orlando, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 4:35 p.m. EST.

• Baxter Reports 2017 Fourth-Quarter and Full-Year Results

  2/1/2018

  Baxter International, Inc. today reported results for the fourth quarter and full-year ended December 31, 2017, and provided its financial guidance for 2018.

• Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin

  1/22/2018

  Baxter announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).

• 

  Puma Hits a Huge Roadblock

  1/17/2018

  Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017.

• Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain Medication Sterility

  1/11/2018

  Baxter today announced a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device.

• Baxter to Host Fourth Quarter 2017 Financial Results Conference Call for Investors

  1/10/2018

  Baxter will host a conference call to discuss its fourth quarter 2017 financial results on Thursday, February 1, 2018, at 7:30 a.m. Central Standard Time.

• Baxter Announces Agreement to Broaden Portfolio of Innovative Surgical Products

  1/8/2018

  Baxter announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction.

• Baxter Declares Quarterly Dividend

  11/14/2017

  The dividend is payable on January 2, 2018, to stockholders of record as of December 1, 2017. The indicated annual dividend rate is $0.64 per share.